Alternative Medicines as Emerging Therapies for Inflammatory Bowel Diseases

REFERENCES

• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.
   PubMed Web of Science ®Google Scholar
• Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis. 2007;8:171–178.
   PubMed Web of Science ®Google Scholar
• Maynard CL, Weaver CT. Intestinal effector T cells in health and disease. Immunity. 2009;31:389–400.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease (1). N Engl J Med. 1991;325:928–937.
   PubMed Web of Science ®Google Scholar
• Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen TI, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med. 1991;324:84–88.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603–606.
   PubMed Web of Science ®Google Scholar
• Bonen DK, Ogura Y, Nicolae DL, Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology. 2003;124:140–146.
   PubMed Web of Science ®Google Scholar
• Mahida YR, Priddle JD, Jewell DP. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Clin Exp Immunol. 1989;78:37–41.
   PubMedGoogle Scholar
• Leong RW, Armuzzi A, Ahmad T, NOD2/CARD15 gene polymorphisms and Crohn's disease in the Chinese population. Aliment Pharmacol Ther. 2003;17:1465–1470.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Hum Genet. 2007;52:575–583.
   PubMed Web of Science ®Google Scholar
• Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology. 1998;114:433–440.
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol. 10:578–587.
   PubMedGoogle Scholar
• Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514–521.
   PubMed Web of Science ®Google Scholar
• Kaser A, Lee AH, Franke A, XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 2008;134:743–756.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463.
   PubMed Web of Science ®Google Scholar
• Festen EA, Goyette P, Scott R, Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut. 2009;58:799–804.
   PubMedGoogle Scholar
• Barrett JC, Hansoul S, Nicolae DL, Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955–962.
   PubMed Web of Science ®Google Scholar
• Garrett WS, Lord GM, Punit S, Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131:33–45.
   PubMed Web of Science ®Google Scholar
• Fort M, Lesley R, Davidson N, IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol. 2001;166:2793–2800.
   PubMedGoogle Scholar
• Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature. 2008;455:396–400.
   PubMed Web of Science ®Google Scholar
• Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75:274–282.
   PubMedGoogle Scholar
• Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75:253–261.
   PubMed Web of Science ®Google Scholar
• Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263–274.
   PubMed Web of Science ®Google Scholar
• Welte T, Zhang SS, Wang T, STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A. 2003;100:1879–1884.
   PubMed Web of Science ®Google Scholar
• Esworthy RS, Aranda R, Martin MG, Doroshow JH, Binder SW, Chu FF. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G848–855.
   PubMed Web of Science ®Google Scholar
• Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63:1099–1112.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin Infect Dis. 2007;44: 256–262.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.
   PubMedGoogle Scholar
• Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577–594.
   PubMed Web of Science ®Google Scholar
• Collins MT. Paratuberculosis: review of present knowledge. Acta Vet Scand. 2003;44:217–221.
   Google Scholar
• Harris NB, Barletta RG. Mycobacterium avium subsp. paratuberculosis in veterinary medicine. Clin Microbiol Rev. 2001;14:489–512.
   PubMed Web of Science ®Google Scholar
• Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev. 1989;2:90–117.
   PubMed Web of Science ®Google Scholar
• McFadden JJ, Butcher PD, Chiodini RJ, Hermon-Taylor J. Determination of genome size and DNA homology between an unclassified Mycobacterium species isolated from patients with Crohn's disease and other mycobacteria. J Gen Microbiol. 1987;133:211–214.
   PubMedGoogle Scholar
• Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut. 1992;33:890–896.
   PubMed Web of Science ®Google Scholar
• Autschbach F, Eisold S, Hinz U, High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease [see comment]. Gut. 2005;54:944–949.
   PubMed Web of Science ®Google Scholar
• Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J Gastroenterol. 2000;95:1094–1095.
   PubMed Web of Science ®Google Scholar
• Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease [see comment]. Lancet. 2004;364:1039–1044.
   PubMed Web of Science ®Google Scholar
• Naser SA, Hulten K, Shafran I, Graham DY, El-Zaatari FA. Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet Microbiol. 2000;77:497–504.
   PubMed Web of Science ®Google Scholar
• Shafran I, Piromalli C, Decker JW, Sandoval J, Naser SA, El-Zaatari FA. Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients. Digest Dis Sci. 2002;47:2079–2081.
   PubMedGoogle Scholar
• Chamberlin W, Graham DY, Hulten K, Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. Aliment Pharmacol Ther. 2001;15:337–346.
   PubMed Web of Science ®Google Scholar
• Hulten K, El-Zimaity HM, Karttunen TJ, Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization [see comment]. Am J Gastroenterol. 2001;96:1529–1535.
   PubMedGoogle Scholar
• Swidsinski A, Ladhoff A, Pernthaler A, Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54.
   PubMed Web of Science ®Google Scholar
• Pierik M, Joossens S, Van Steen K, Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis. 2006;12:1–8.
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P, A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207–211.
   PubMed Web of Science ®Google Scholar
• Rioux JD, Xavier RJ, Taylor KD, Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596–604.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Juni P, Bekkering GE, Genetic evidence supporting the association of protease and protease inhibitor genes with inflammatory bowel disease: a systematic review. PLoS One. 2011;6:e24106.
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers CJ, Yang H, Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005;128: 2020–2028.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003;38:180–185.
   PubMed Web of Science ®Google Scholar
• Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol. 2011;5:703–716.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Pallone F, Macdonald TT. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol. 2011;11(6):640–645.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12:4807–4812.
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh S, Taub DD, Lillard JW Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10(-/-) mice. J Immunol. 2003;171:1401–1406.
   PubMed Web of Science ®Google Scholar
• Uguccioni M, Gionchetti P, Robbiani DF, Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol. 1999;155:331–336.
   PubMed Web of Science ®Google Scholar
• Walz A, Schmutz P, Mueller C, Schnyder-Candrian S. Regulation and function of the CXC chemokine ENA-78 in monocytes and its role in disease. J Leukocyte Biol. 1997;62:604–611.
   PubMedGoogle Scholar
• Soto H, Wang W, Strieter RM, The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. Proc Natl Acad Sci U S A. 1998;95:8205–8210.
   PubMed Web of Science ®Google Scholar
• Shibahara T, Wilcox JN, Couse T, Madara JL. Characterization of epithelial chemoattractants for human intestinal intraepithelial lymphocytes. Gastroenterology. 2001;120:60–70.
   PubMed Web of Science ®Google Scholar
• Scheerens H, Hessel E, de Waal-Malefyt R, Leach MW, Rennick D. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Eur J Immunol. 2001;31:1465–1474.
   PubMed Web of Science ®Google Scholar
• Russel MG, Stockbrugger RW. Epidemiology of inflammatory bowel disease: an update. Scand J Gastroenterol. 1996;31:417–427.
   PubMed Web of Science ®Google Scholar
• Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001:29–40.
   PubMedGoogle Scholar
• Jonkers D, Stockbrugger R. Probiotics and inflammatory bowel disease. J R Soc Med. 2003;96:167–171.
   PubMed Web of Science ®Google Scholar
• Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol. 2010;300:25–33.
   PubMed Web of Science ®Google Scholar
• Salminen S, Bouley C, Boutron-Ruault MC, Functional food science and gastrointestinal physiology and function. Br J Nutr. 1998;80 Suppl 1:S147–S171.
   PubMed Web of Science ®Google Scholar
• Dunne C, O'Mahony L, Murphy L, In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr. 2001;73:386S–392S.
   PubMed Web of Science ®Google Scholar
• Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis. 2000;6:107–115.
   PubMed Web of Science ®Google Scholar
• Schultz M, Veltkamp C, Dieleman LA, Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis. 2002;8: 71–80.
   PubMed Web of Science ®Google Scholar
• Mao Y, Nobaek S, Kasravi B, The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996;111:334–344.
   PubMed Web of Science ®Google Scholar
• Hart AL, Lammers K, Brigidi P, Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut. 2004;53:1602–1609.
   PubMed Web of Science ®Google Scholar
• Neish AS, Gewirtz AT, Zeng H, Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000;289:1560–1563.
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114.
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462–1464.
   PubMed Web of Science ®Google Scholar
• Soo I, Madsen KL, Tejpar Q, VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol. 2008;22:237–242.
   PubMed Web of Science ®Google Scholar
• Pronio A, Montesani C, Butteroni C, Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14:662–668.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997;40:775–781.
   PubMed Web of Science ®Google Scholar
• Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8:549–553.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rochon J, Fedorak RN, Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292–297.
   PubMed Web of Science ®Google Scholar
• Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:417–427.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443–448.
   PubMedGoogle Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW, Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109: 129–135.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• van Deventer SJ. Review article: chemokine production by intestinal epithelial cells: a therapeutic target in inflammatory bowel disease? Aliment Pharmacol Ther. 1997;11 (Suppl 3):116–120; discussion 120–111.
   PubMedGoogle Scholar
• Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Therapeut. 1999;21:932–942; discussion 931.
   PubMed Web of Science ®Google Scholar
• Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity. 1994;1:553–562.
   PubMed Web of Science ®Google Scholar
• Berg DJ, Davidson N, Kuhn R, Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010–1020.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182–1197.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127.
   PubMed Web of Science ®Google Scholar
• Qin S, Rottman JB, Myers P, The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101:746–754.
   PubMed Web of Science ®Google Scholar
• Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol. 2000;108:227–235.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leukemia Lymphoma. 2000;38:363–371.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Tutiya T, Yamaguchi T, Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer. 2002;98:567–572.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Rotondi M, Lazzeri E, Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves’ disease. Am J Pathol. 2002;161:195–206.
   PubMed Web of Science ®Google Scholar
• Romagnani P, Beltrame C, Annunziato F, Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol. 1999;10:2518–2526.
   Google Scholar
• Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol. 2001;167:4091–4097.
   PubMedGoogle Scholar
• Salmaggi A, Gelati M, Dufour A, Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res. 2002;22:631–640.
   PubMedGoogle Scholar
• Belperio JA, Keane MP, Burdick MD, Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol. 2002;169:1037–1049.
   PubMed Web of Science ®Google Scholar
• Agostini C, Cassatella M, Zambello R, Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol. 1998;161:6413–6420.
   PubMed Web of Science ®Google Scholar
• Flier J, Boorsma DM, van Beek PJ, Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation [comment]. J Pathol. 2001;194:398–405.
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh S, Singh R, Cong Y, Taub DD, Lillard JW Jr. CXCL10-producing mucosal CD4+ T cells, NK cells, and NKT cells are associated with chronic colitis in IL-10(-/-) mice, which can be abrogated by anti-CXCL10 antibody inhibition. J Interferon Cytokine Res. 2008;28:31–43.
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh S, Weaver CT, Iqbal N, McGhee JR, Lillard JW, Jr. IFN-g- inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res. 2003;23:2000.
   Google Scholar
• Hyun JG, Lee G, Brown JB, Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis. 2005;11:799–805.
   PubMed Web of Science ®Google Scholar
• Head K, Jurenka JS. Inflammatory bowel disease, II: Crohn's disease—pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2004;9:360–401.
   PubMedGoogle Scholar
• Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther. 2002;16:197–205.
   PubMed Web of Science ®Google Scholar
• Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.
   PubMed Web of Science ®Google Scholar
• de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005;49:405–430.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220.
   PubMed Web of Science ®Google Scholar
• Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J. 2005;19:840–841.
   PubMed Web of Science ®Google Scholar
• Martin AR, Villegas I, Sanchez-Hidalgo M, de la Lastra CA. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol. 2006;147:873–885.
   PubMed Web of Science ®Google Scholar
• Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol. 2004;67:1399–1410.
   PubMed Web of Science ®Google Scholar
• Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol. 2011;82:737–745.
   PubMed Web of Science ®Google Scholar
• Biasi F, Astegiano M, Maina M, Leonarduzzi G, Poli G. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem. 2011.
   PubMedGoogle Scholar
• Singh UP, Singh NP, Singh B, Resveratrol (trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther. 2010;332:829–839.
   PubMed Web of Science ®Google Scholar
• Cui X, Jin Y, Hofseth AB, Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila Pa) 2010;3:549–559.
   PubMed Web of Science ®Google Scholar
• Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57:1–7.
   PubMed Web of Science ®Google Scholar
• Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986;24:651–654.
   PubMed Web of Science ®Google Scholar
• Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol. 2002;40:1091–1097.
   PubMed Web of Science ®Google Scholar
• Toda S, Miyase T, Arichi H, Tanizawa H, Takino Y. Natural antioxidants, III: antioxidative components isolated from rhizome of Curcuma longa L. Chem Pharm Bull (Tokyo). 1985;33:1725–1728.
   PubMed Web of Science ®Google Scholar
• Hanif R, Qiao L, Shiff SJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med. 1997;130:576–584.
   PubMed Web of Science ®Google Scholar
• Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. Adv Exp Med Biol. 2007;595:127–148.
   PubMed Web of Science ®Google Scholar
• Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med. 2007;19:469–474.
   PubMed Web of Science ®Google Scholar
• Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des. 2009;15:2087–2094.
   PubMed Web of Science ®Google Scholar
• Plummer SM, Holloway KA, Manson MM, Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene. 1999;18:6013–6020.
   PubMed Web of Science ®Google Scholar
• Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191–2193.
   PubMed Web of Science ®Google Scholar
• Taylor RA, Leonard MC. Curcumin for inflammatory bowel disease: a review of human studies. Altern Med Rev. 2011;16:152–156.
   PubMedGoogle Scholar
• Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol. 2005;116:135–142.
   PubMed Web of Science ®Google Scholar
• Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med. 2000;132:680.
   PubMed Web of Science ®Google Scholar
• Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol. 2008;128:66–74.
   PubMed Web of Science ®Google Scholar
• Hale LP, Chichlowski M, Trinh CT, Greer PK. Dietary supplementation with fresh pineapple juice decreases inflammation and colonic neoplasia in IL-10-deficient mice with colitis. Inflamm Bowel Dis. 2010;16:2012–2021.
   PubMed Web of Science ®Google Scholar
• Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 2002;42:25–54.
   PubMed Web of Science ®Google Scholar
• Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr. 2004;134:1039–1044.
   PubMed Web of Science ®Google Scholar
• Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol. 2001;60:528–533.
   PubMed Web of Science ®Google Scholar
• Na HK, Surh YJ. Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol Nutr Food Res. 2006;50:152–159.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Fuss I, Schurmann G, Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci. 1998;859:149–159.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998;42:477–484.
   PubMed Web of Science ®Google Scholar
• Mazzon E, Muia C, Paola RD, Green tea polyphenol extract attenuates colon injury induced by experimental colitis. Free Radic Res. 2005;39:1017–1025.
   PubMed Web of Science ®Google Scholar
• Varilek GW, Yang F, Lee EY, Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J Nutr. 2001;131:2034–2039.
   PubMed Web of Science ®Google Scholar
• Kim M, Murakami A, Miyamoto S, Tanaka T, Ohigashi H. The modifying effects of green tea polyphenols on acute colitis and inflammation-associated colon carcinogenesis in male ICR mice. Biofactors. 2010;36:43–51.
   PubMed Web of Science ®Google Scholar
• Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16:297–304.
   PubMed Web of Science ®Google Scholar
• Abboud PA, Hake PW, Burroughs TJ, Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol. 2008;579:411–417.
   PubMed Web of Science ®Google Scholar
• Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition. 2008;24:733–743.
   PubMed Web of Science ®Google Scholar
• Toklu HZ, Dumlu MU, Sehirli O, Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats. J Pharm Pharmacol. 2007;59:1287–1295.
   PubMed Web of Science ®Google Scholar
• Adhami VM, Mukhtar H. Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer. Mol Biotechnol. 2007;37:52–57.
   PubMedGoogle Scholar
• Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S. Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol (Tokyo). 2006;52:383–388.
   PubMed Web of Science ®Google Scholar
• Aviram M, Volkova N, Coleman R, Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem. 2008;56:1148–1157.
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Watanabe Y, Kasai K, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and ultraviolet-induced pigmentation. Biosci Biotechnol Biochem. 2005;69:2368–2373.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Kanatsu K, Iino T, Protection against dextran sulfate sodium-induced colitis by microspheres of ellagic acid in rats. Life Sci. 2002;71:827–839.
   PubMed Web of Science ®Google Scholar
• Singh K, Jaggi AS, Singh N. Exploring the ameliorative potential of Punica granatum in dextran sulfate sodium induced ulcerative colitis in mice. Phytother Res. 2009;23:1565–1574.
   PubMed Web of Science ®Google Scholar
• Larrosa M, Gonzalez-Sarrias A, Yanez-Gascon MJ, Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem. 2010;21:717–725.
   PubMed Web of Science ®Google Scholar
• Kampkotter A, Nkwonkam CG, Zurawski RF, Investigations of protective effects of the flavonoids quercetin and rutin on stress resistance in the model organism Caenorhabditis elegans. Toxicology. 2007;234:113–123.
   PubMed Web of Science ®Google Scholar
• Kwon KH, Murakami A, Tanaka T, Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol. 2005;69:395– 406.
   PubMed Web of Science ®Google Scholar
• Kim H, Kong H, Choi B, Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res. 2005;22:1499–1509.
   PubMed Web of Science ®Google Scholar
• Cruz T, Galvez J, Ocete MA, Crespo ME, Sanchez de Medina LHF, Zarzuelo A. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci. 1998;62:687–695.
   PubMedGoogle Scholar
• Belluzzi A. N-3 fatty acids for the treatment of inflammatory bowel diseases. Proc Nutr Soc. 2002;61:391–395.
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr. 2000;71:339S-342S.
   Google Scholar
• MacLean CH, Mojica WA, Morton SC, Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid Rep Technol Assess (Summ). 2004:1–4.
   PubMedGoogle Scholar
• Hawthorne AB, Daneshmend TK, Hawkey CJ, Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut. 1992;33:922–928.
   PubMed Web of Science ®Google Scholar
• Loeschke K, Ueberschaer B, Pietsch A, n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci. 1996;41:2087–2094.
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334:1557–1560.
   PubMed Web of Science ®Google Scholar
• Speranza G, Morelli CF, Tubaro A, Altinier G, Duri L, Manitto P. Aloeresin I, an anti-inflammatory 5-methylchromone from cape aloe. Planta Med. 2005;71:79–81.
   PubMed Web of Science ®Google Scholar
• Takzare N, Hosseini MJ, Hasanzadeh G, Mortazavi H, Takzare A, Habibi P. Influence of aloe vera gel on dermal wound healing process in rat. Toxicol Mech Methods. 2009;19:73–77.
   PubMed Web of Science ®Google Scholar
• Park MY, Kwon HJ, Sung MK. Dietary aloin, aloesin, or aloe-gel exerts anti-inflammatory activity in a rat colitis model. Life Sci. 2011;88:486–492.
   PubMed Web of Science ®Google Scholar
• Langmead L, Feakins RM, Goldthorpe S, Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:739–747.
   PubMed Web of Science ®Google Scholar
• Gupta I, Parihar A, Malhotra P, Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2:37–43.
   PubMedGoogle Scholar
• Gupta I, Parihar A, Malhotra P, Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67:391–395.
   PubMed Web of Science ®Google Scholar
• Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002;37:444–449.
   PubMed Web of Science ®Google Scholar
• Millar AD, Rampton DS, Chander CL, Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39:407–415.
   PubMed Web of Science ®Google Scholar
• Ademoglu E, Erbil Y, Tam B, Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci. 2004;49:102–108.
   PubMedGoogle Scholar
• Bitiren M, Karakilcik AZ, Zerin M, Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res. 2010;136: 87–95.
   PubMedGoogle Scholar
• Reifen R, Nissenkorn A, Matas Z, Bujanover Y. 5-ASA and lycopene decrease the oxidative stress and inflammation induced by iron in rats with colitis. J Gastroenterol. 2004;39:514–519.
   PubMed Web of Science ®Google Scholar
• Beattie RM, Bentsen BS, MacDonald TT. Childhood Crohn's disease and the efficacy of enteral diets. Nutrition. 1998;14:345–350.
   PubMed Web of Science ®Google Scholar
• Escher JC, Taminiau JA. Treatment of inflammatory bowel disease in childhood. Scand J Gastroenterol Suppl. 2001:48–50.
   PubMedGoogle Scholar
• Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8–15.
   PubMed Web of Science ®Google Scholar
• Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20:167–172.
   PubMedGoogle Scholar
• Teahon K, Smethurst P, Pearson M, Levi AJ, Bjarnason I. The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease. Gastroenterology. 1991;101:84–89.
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Heizer WD. Nutritional issues in inflammatory bowel disease. Gastroenterol Clin North Am. 1998;27:435–451.
   PubMed Web of Science ®Google Scholar
• Borrelli O, Cordischi L, Cirulli M, Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–753.
   PubMed Web of Science ®Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology. 1995;108:1056–1067.
   PubMed Web of Science ®Google Scholar
• Messori A, Trallori G, D'Albasio G, Milla M, Vannozzi G, Pacini F. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol. 1996;31:267–272.
   PubMed Web of Science ®Google Scholar
• Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut. 2006;55:356–361.
   PubMed Web of Science ®Google Scholar
• Rubio A, Pigneur B, Garnier-Lengline H, The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33:1332–1339.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Lamosa ML, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Design of microencapsulated chitosan microspheres for colonic drug delivery. J Control Release. 1998;52:109–118.
   PubMed Web of Science ®Google Scholar
• Jain SK, Jain A, Gupta Y, Ahirwar M. Design and development of hydrogel beads for targeted drug delivery to the colon. AAPS PharmSciTech. 2007; 8:E56.
   Google Scholar
• Bigucci F, Luppi B, Cerchiara T, Chitosan/pectin polyelectrolyte complexes: selection of suitable preparative conditions for colon-specific delivery of vancomycin. Eur J Pharm Sci. 2008;35:435–441.
   PubMed Web of Science ®Google Scholar
• Orienti I, Cerchiara T, Luppi B, Bigucci F, Zuccari G, Zecchi V. Influence of different chitosan salts on the release of sodium diclofenac in colon-specific delivery. Int J Pharm. 2002;238:51–59.
   PubMed Web of Science ®Google Scholar
• Mura C, Nacher A, Merino V, N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats. Int J Pharm. 2011;416:145–154.
   PubMed Web of Science ®Google Scholar